Pith. sign in

Reference change · event page

Reference changes · DOI

Sunitinib plus paclitaxel versus bevacizumab plus paclitaxel for first-line treatment of patients with advanced breast cancer: A phase III, randomized, open-label trial

Published notice on a work cited in the Pith corpus. Exact quotes below. No model judges whether any citation was load-bearing.

This page records that a citing paper's bibliography includes a work with a published notice. It is not a judgment on the citing paper.

Correction Crossref 1 open · 1 total · 0 disputed
DOI
10.1016/j.clbc.2011.03.005
Notice DOI
10.1016/j.clbc.2011.06.004
Event date
2011-08-03
Machine twin
JSON

01One-hop citing occurrences

Correction Open
Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab

ref [9] · 2501.08744 · notice #9648 · dispute

Raw extraction · citation context

for HER2-positive locally recurrent/metastatic breast cancer. J Clin Oncol 2013; 31: 1719- 1725. 20130408. DOI: 10.1200/jco.2012.44.7912. 50. Robert NJ, Saleh MN, Paul D, et al. Sunitinib plus paclitaxel versus bevacizumab plus paclitaxel for first-line treatment of patients with advanced breast cancer: A phase III, randomized, open-label trial. Clin Breast Cancer 2011; 11: 82-92. 20110411. DOI: 10.1016/j.clbc.2011.03.005. 51. Martín M, Roche H, Pinter T, et al. Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or 26 metastatic breast cancer: A phase 2, randomised, double-blind, placebo-controlled study. Lancet Oncol 2011; 12: 369-376. 20110321. DOI: 10.1016/s1470-2045(11)70037-7.

Parser render (TeX stripped for reading; raw above is the evidence)

for HER2-positive locally recurrent/metastatic breast cancer. J Clin Oncol 2013; 31: 1719- 1725. 20130408. DOI: 10.1200/jco.2012.44.7912. 50. Robert NJ, Saleh MN, Paul D, et al. Sunitinib plus paclitaxel versus bevacizumab plus paclitaxel for first-line treatment of patients with advanced breast cancer: A phase III, randomized, open-label trial. Clin Breast Cancer 2011; 11: 82-92. 20110411. DOI: 10.1016/j.clbc.2011.03.005. 51. Martín M, Roche H, Pinter T, et al. Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or 26 metastatic breast cancer: A phase 2, randomised, double-blind, placebo-controlled study. Lancet Oncol 2011; 12: 369-376. 20110321. DOI: 10.1016/s1470-2045(11)70037-7

Status lifecycle on notices: open → disputed → (response attached on the notice page). Repaired counts matter as much as open counts. There is no “safe,” “invalid,” or “resolved” badge.